Profile data is unavailable for this security.
About the company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
- Revenue in HKD (TTM)4.75bn
- Net income in HKD-326.19m
- Incorporated2000
- Employees1.97k
- LocationHUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
- Phone+852 21281188
- Fax+852 21281778
- Websitehttps://www.hutch-med.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3SBio Inc | 9.20bn | 1.81bn | 13.97bn | 5.61k | 7.84 | 0.8889 | 6.21 | 1.52 | 0.7437 | 0.7437 | 3.78 | 6.56 | 0.3575 | 1.52 | 6.87 | 1,700,070.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 16.19bn | 10.78k | 6.62 | 1.03 | 5.63 | 1.53 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Simcere Pharmaceutical Group Ltd | 6.93bn | -1.21bn | 17.74bn | 6.41k | -- | 2.37 | -- | 2.56 | -0.4604 | -0.4604 | 2.69 | 2.97 | 0.5198 | 2.19 | 2.64 | 985,844.90 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| China Medical System Holdings Ltd | 7.66bn | 1.52bn | 19.00bn | 5.78k | 12.53 | 1.08 | 10.79 | 2.48 | 0.6216 | 0.6216 | 3.13 | 7.19 | 0.384 | 2.89 | 5.65 | 1,343,944.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| The United Laboratories Intl. Hldgs Ltd. | 15.30bn | 3.18bn | 19.19bn | 15.00k | 6.04 | 1.30 | 5.05 | 1.25 | 1.75 | 1.75 | 8.42 | 8.13 | 0.6578 | 3.30 | 5.67 | 1,020,171.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Zai Lab Ltd | 2.51bn | -2.32bn | 23.81bn | 2.18k | -- | 4.29 | -- | 9.49 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| HUTCHMED (China) Ltd | 4.75bn | -326.19m | 24.75bn | 1.97k | -- | 4.30 | -- | 5.21 | -0.3881 | -0.3881 | 5.50 | 6.60 | 0.4775 | 7.10 | 4.15 | 2,387,889.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.05bn | 649.44m | 27.71bn | 1.50k | 43.29 | 4.23 | 37.46 | 9.07 | 0.5336 | 0.5336 | 2.70 | 5.46 | 0.5586 | 21.31 | 2.85 | 2,592,253.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 273.68bn | 4.12bn | 34.55bn | 72.76k | 8.38 | 0.654 | 2.74 | 0.1263 | 0.6564 | 0.6564 | 43.56 | 8.41 | 0.966 | 6.09 | 3.28 | 3,749,788.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 02 Nov 2023 | 43.17m | 4.95% |
| Canada Pension Plan Investment Boardas of 15 May 2023 | 25.86m | 2.97% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 17.87m | 2.05% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 16.51m | 1.89% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 13.92m | 1.60% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 12.39m | 1.42% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 10.61m | 1.22% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 8.33m | 0.96% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Aug 2024 | 7.90m | 0.91% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 7.20m | 0.83% |
